Overview of ecallantide in the treatment of hereditary angioedema types i and II

Therapy

Volumn 7, Issue 5, 2010, Pages 565-571

  Banta, Erin ^a   Craig, Timothy J ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

C1 esterase inhibitor; ecallantide; hereditary angioedema; pharmacology; plasma kallikrein

Indexed keywords

ANDROGEN; ANTIHISTAMINIC AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID DERIVATIVE; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; KALBITOR; KALLIKREIN INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; BLEEDING DISORDER; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EMBRYOTOXICITY; FATIGUE; FETOTOXICITY; HOT FLUSH; HUMAN; HYPOTENSION; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE URTICARIA; MORBIDITY; MORTALITY; NAUSEA; NOSE CONGESTION; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; THORAX PAIN; THROAT IRRITATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WHEEZING;

EID: 77957126428     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.10.49     Document Type: Review

References (33)

1. Zuraw BL: Clinical practice. Hereditary angioedema. N. Engl. J. Med. 359(10), 1027-1036 (2008).
2. Bork K, Barnstedt SE, Koch P, Traupe H: Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356(9225), 213-217 (2000).
3. Agostoni A, Aygoren-Pursun E, Binkley KE et al.: Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol. 114(Suppl. 3), S51-S131 (2004).
4. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M: C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol. Med. 15(2), 69-78 (2009).
5. Gompels MM, Lock RJ, Abinun M et al.: C1 inhibitor deficiency: consensus document. Clin. Exp. Immunol. 139(3), 379-394 (2005).
6. Bork K, Meng G, Staubach P, Hardt J: Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am. J. Med. 119(3), 267-274 (2006).
7. Ohela K, Rasanen JA, Wager O: Hereditary angio-neurotic oedema. Genealogical and immunological studies. Ann. Clin. Res. 5(3), 174-180 (1973).
8. Zuraw B, Yasothan U, Kirkpatrick P: Ecallantide. Nat. Rev. Drug Discov. 9, 189-190 (2010).
9. Bernstein JA, Qazi M: Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev. Clin. Immunol. 6(1), 29-39 (2010).
10. Craig T, Levy RJ, Wasserman RL et al.: Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J. Allergy Clin. Immunol. 124, 801-808 (2009).
11. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W: Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J. Allergy Clin. Immunol. 119(6), 1497-1503 (2007).
12. Kemp JG, Craig TJ: Variability of prodromal signs and symptoms associated with hereditary angioedema attacks: a literature review. Allergy Asthma Proc. 30(5), 493-499 (2009).
13. Prematta MJ, Kemp JG, Gibbs JG, Mende C, Rhoads C, Craig TJ: Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Asthma Proc. 30(5), 506-511 (2009).
14. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A: Plasma bradykinin in angio-oedema. Lancet 351, 1693-1697 (1998).
15. Nussberger J, Cugno M, Cicardi M, Agostoni A: Local bradykinin generation in hereditary angioedema. J. Allergy Clin. Immunol. 104, 1321-1322 (1999).
16. Nussberger J, Cugno M, Cicardi M: Bradykinin-mediated angioedema. N. Engl. J. Med. 347(8), 621-622 (2002).
17. Bas M, Hoffman TK, Bier H, Kojda G: Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br. J. Clin. Pharmacol. 59(2), 233-238 (2005).
18. Taki M, Watanabe H, Hasegawa T, Bamba H, Shimada T, Hisa Y: Angioedema: 6 years experience with fourteen cases. Auris Nasus Larynx 37(2), 199-204 (2010).
19. Cugno M, Zanichelli A, Bellatorre AG, Griffini S, Cicardi M: Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 64, 254-257 (2009).
20. Bowen T, Cicardi M, Bork K et al.: Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann. Allergy Asthma Immunol. 100(1 Suppl. 2), S30-S40 (2008).
21. Christiansen SC, Zuraw BL: Update on therapeutic developments for hereditary angioedema. Allergy Asthma Proc. 30(5), 500-505 (2009).
22. Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T: Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 120(2), 416-422 (2007).
23. Williams A, Baird LG: DX-88 and HAE: a developmental perspective. Transfus. Apher. Sci. 29(3), 255-258 (2003).
24. KALBITOR, prescribing information. Dyax Corp, MA, USA (2009).
25. Tanaka KA, Szlam F, Katori N, Vega JD, Levy JH: Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb. Res. 113(5), 333-339 (2004).
26. Levy RJ, Lumry WR, McNeil DL et al.: EDEMA4: a Phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann. Allergy Asthma Immunol. 104(6), 523-529 (2010).
27. Vernon MK, Rentz AM, Wyrwich KW, White MV, Grienenberger A: Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual. Life Res. 18(7), 929-939 (2009).
28. Cicardi, M, Levy RJ, McNeil DL et al.: Ecallantide for the treatment of acute attacks in hereditary angioedema. N. Engl. J. Med. 363, 523-531 (2010).
29. Sampson HA, Munoz-Furlong A, Campbell RL et al.: Second symposium on the definition and management of anaphylaxis: summary report - second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J. Allergy Clin. Immunol. 117(2), 391-397 (2006).
30. Rezvani M, Bernstein DI: Anaphylactic reactions during immunotherapy. Immunol. Allergy Clin. N. Am. 27, 295-307 (2007).
31. Pharming Press Release: Pharming confirms positive results from final analysis of Rhucin studies www.tradingmarkets.com/.site/news/ Stock%20News/2399906 (Accessed 29th April 2010)
32. Pharming Press Release June 2010 www.pharming.com (Accessed 30th June 2010)
33. Advisory Committee Briefing Document: Kalbitor (ecallantide) for acute attacks of hereditary angioedema (BLA 125277) www.fda.gov/downloads/ AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ Pulmonary- AllergyDrugsAdvisoryCommittee/ UCM170334.pdf (Accessed 28th May 2010)